RxDoctor Payments Data

Shalini Sood, MD

Glaucoma Specialist · Independence, OHNPI 1467497818

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 54.5% of the total. Reporting peaked in 2021 at $12,764 and has fallen 96.8% since, to $407 in 2025.

$30,188in general payments, 2019–2025

Across 72 payments — averaging $419.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$16K
  • Ocular Therapeutix, Inc.$5K
  • Sight Sciences, Inc.$5K
  • Alcon$1K
  • Ivantis, Inc$1K
  • AbbVie$906
  • plus $469 from 3 others

What the payments were for

  • Consulting fees$9,57532%
  • Speaking & faculty fees$17,57558%
  • Food & beverage$2,93910%
  • Education$820%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$272,664
Medicare patients
798
Services billed
3,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost141$74,789
RestasisCyclosporine60$68,267
RhopressaNetarsudil Mesylate147$56,932
XiidraLifitegrast52$55,747
Brimonidine Tartrate665$37,692
CombiganBrimonidine Tartrate/Timolol89$33,851
Latanoprost2,185$30,866
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,317$22,346
VyzultaLatanoprostene Bunod29$19,690
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol113$19,646
Prednisolone Acetate402$18,163
Cyclosporine26$16,111
RocklatanNetarsudil Mesylat/Latanoprost35$15,676
Dorzolamide-TimololDorzolamide/Timolol/Pf62$13,818
Timolol Maleate434$10,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$906$183,633314 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$253$72,608182 claims
AlconSimbrinza$1,032$9,07733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Independence

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →